This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s (formerly Cancer Genetics, Inc.) expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve profitability and increase sales of our pre-clinical services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger with StemoniX, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio, Inc. disclaims any obligation to update these forward-looking statements.
DRUG DISCOVERY
Needs A Paradigm Shift

Widely used models for predicting drug efficacy & safety have underperformed

Human biology is introduced late in the R&D process resulting in high failure rates & costs

Vyant Bio
Defines The New Approach

HIGHLY FUNCTIONAL HUMAN organoids at industrial SCALE

DATA SCIENCE brings quantified human data to the EARLIEST pipeline stages

OPTIMIZED THERAPEUTIC EFFICACY & SAFETY

StemoniX's microBrain® human neurosphere
**Strategic Value Proposition**

**Human-First Drug Discovery Engine:**

- **StemoniX**
- **Discovery Engine**
- **CGIX-vivoPharm**

- Industrialized Human Spheroids (Discovery)
- Data Science
- Machine Learning
- Global Pharma Partners

- Cancer Big Data
- Tumor Line Library
- Global Partners
- Efficacy & Safety Data
- Late Stage
- Preclinical Experts
- *In Vivo* Research

**Vertically Integrated Development**

- World-leading human spheroid technology is predictive of success. Biology- and AI-enabled Data Science; Seasoned *In Vivo* Expertise

**Global Partnership Footprint**

- Leading Pharma Partners
- Validated Human Model Platforms
- Trusted Pre-clinical & Regulatory Capabilities

**Multi-shot on Goal Drug Discovery**

- High-Throughput Human Pre-clinical Screening
- Modality Convergence (Novel *In Vitro* Biology + Software + *In Vivo* Studies)
Strategic Value Throughout the Pipeline
Patient 1st disease platforms, AI/ML hit discovery & human-based validation, Preclinical development, IND filing

Vyant Bio Optimized Human-First Models

Early Discovery Platform
- Target ID & Validation
- Lead Identification
- Lead Optimization
- Preclin. Studies (ADME-Tox)
- IND Filing

AI-based In Silico Screening

Human iPSC-Spheroids
- Disease Models
  - Patient Derived
  - Genetically Engineered
- Disease Phenotype
  - Functional difference from control
- Human-based disease model for HT drug discovery.

Assay Development Phenotypic Screening
- High-Content Imaging
- Functional (FLIPR)
- Targeted Library-Based
- Repositioning possible
- AI/ML Assisted
- Assay AnalytiX™

Identify Novel Targets
Orthogonal Validation
Rank-order results
Rapid HT screening w/ novel target ID

Target-to-Hit & Hit-to-Lead Screening
- Efficacy/Toxicity
- Rank Ordering Validation
- Molecular Profiling
- High-Content Imaging
AI/ML Assisted
- Assay AnalytiX™
- AtomNet in silico screening

Billions of potential molecules to the best compounds

Screening
Rapid Medicinal Chem.
- Iterative in silico screening
- Empirical verification
Identify the best, novel candidates & target(s).
- High-Content Imaging
- Molecular Profiling
- Mechanism of Action
- Druggable features
The right candidates based on efficacy / safety.

GLP Studies
Highest probability of success
- Identified from billions of molecules
- Vetted through clinically relevant human systems
- Effective and Safe
High confidence for successful clinical translation.

Regulatory Expertise
- Global Regulatory Access
- Data Management
- Regulatory Submissions
Seasoned guidance for Regulatory submissions.

Vyant Bio Development and Regulatory Experience

Human Novel Biology + In Vivo Support + AI/ML

CONFIDENTIAL
Discovery In Action

Highly-scalable platform for early discovery, pre-clinical, and pharmacology provides guidance, preparation of samples, and clinical trial design.

200+ \textit{in vitro} and \textit{in vivo} testing for Investigational New Drug ("IND") applications

20+ INDICATIONS

50+ CNS, CARDIAC, AND ONCOLOGY STUDIES & TRIALS*

5 STATE-OF-THE-ART LABS

* CNS and Cardiac are from StemoniX and Oncology are from vivoPharm
# Proven Team  Led By Passion

<table>
<thead>
<tr>
<th>Jay Roberts, MBA</th>
<th>Ping Yeh, MS MBA</th>
<th>Robert Petcavich, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chief Executive Officer</strong></td>
<td><strong>Chief Innovation Officer</strong></td>
<td><strong>Interim Chief Science Officer</strong></td>
</tr>
<tr>
<td>30+ years healthcare executive leader</td>
<td>Cofounder/CEO of StemoniX and nanotechnologist</td>
<td>Cofounder/CSO of StemoniX</td>
</tr>
<tr>
<td>50+ capital markets and M&amp;A transactions</td>
<td>Brought multiple innovations to market in the semiconductor and storage industries</td>
<td>30+ years experienced Senior Executive of public and PE-backed biotech and medical device companies</td>
</tr>
<tr>
<td>17 years in public company leadership roles with multiple premium exits</td>
<td>Formed and led multiple global teams in technology development</td>
<td>Ph.D. Chemistry, Polymer Science</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Andy LaFrence, CPA</th>
<th>Ralf Brandt, PhD</th>
<th>Barb Jones, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chief Financial Officer</strong></td>
<td><strong>President, Discovery Services</strong></td>
<td><strong>SVP, External and Regulatory Affairs</strong></td>
</tr>
<tr>
<td>KPMG Audit Partner &amp; IPO Readiness Practice</td>
<td>25+ years in biochemistry and cell biology</td>
<td>20+ years international standards, regulatory, and health leadership</td>
</tr>
<tr>
<td>Ten years of operational CFO experience, including 5 years at public companies</td>
<td>Co-founder of international vivoPharm drug discovery CRO</td>
<td>Quality, compliance, and scientific collaboration expertise</td>
</tr>
<tr>
<td>36 years providing financial and business strategy</td>
<td>Lead scientist at Novartis and in vivo pharmaceutical testing expertise</td>
<td>National Lab R&amp;D and pharma manufacturing background</td>
</tr>
</tbody>
</table>
# World Class Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>John Fletcher, MBA</strong></td>
<td>Chairman</td>
<td>30+ years Life Science Executive  &lt;br&gt;CEO/Fletcher Spaght - MD/Fletcher Spaght Ventures  &lt;br&gt;Board of Koru Medical, Clear Point Neuro, Axcelis  &lt;br&gt;NACD Board Member of the Year 2018</td>
</tr>
<tr>
<td><strong>Joanna Horobin, M.B., Ch.B.</strong></td>
<td>Director, Chair Governance Committee</td>
<td>30+ years Drug Developer and Biotech Leader  &lt;br&gt;Chair – iOnctura SA, Board of Kymera Therapeutics, Nordic Nanovector, Liquidia Technologies  &lt;br&gt;CMO of Idera Pharmaceuticals  &lt;br&gt;CEO of Syndax Therapeutics</td>
</tr>
<tr>
<td><strong>Marcus Boehm Ph.D.</strong></td>
<td>Director</td>
<td>Cofounder and CSO of Escent Pharmaceuticals  &lt;br&gt;Cofounder and CTO of Receptos, Inc. acquired by Celgene  &lt;br&gt;Cofounder of Conforma Therapeutics  &lt;br&gt;NIH Postdoctoral Fellowship at Columbia</td>
</tr>
<tr>
<td><strong>Paul Hansen, MBA</strong></td>
<td>Director</td>
<td>25+ years experience in executive leadership roles with 3-M corporation  &lt;br&gt;Cofounder and CEO Minnepura Technologies  &lt;br&gt;President/CEO 3M Mexico, 3M Consumer Healthcare, Executive Director 3M in EMEA</td>
</tr>
<tr>
<td><strong>Geoff Harris, M.S.</strong></td>
<td>Director, Chair Audit Committee</td>
<td>30+ years Life Science Investor and Analyst  &lt;br&gt;Managing Director C7 Advisors – Life Science Investor  &lt;br&gt;Healthcare Investment Banking at Cantor Fitzgerald and Gleacher</td>
</tr>
<tr>
<td><strong>Howard McLeod, PharmD</strong></td>
<td>Director, Chair Compensation Committee</td>
<td>25+ years Pharmacogenomics, Applied Therapeutics and Clinical Pharmacology  &lt;br&gt;Medical Director - DeBartolo Personalized Medicine  &lt;br&gt;Senior Member Moffitt Cancer Center  &lt;br&gt;Founding Director UNC Institute for Pharmacogenomics and Individualized Therapy</td>
</tr>
</tbody>
</table>
Convergence Of Biology and Computing

Industrialized Highly-Functional Human Spheroids

Disease Models
- Brain: Neurodevelopment, Neurodegen.
- Cardiac: Fibrosis
- Pancreas: Diabetes
- Oncology Models (brain, pancreas)

Analytics
- AnalytiX™ Software Technologies
  - Data Science, Analytics, ML

Analytical Tools
- Drugs rank-ordered by parameter performance
- Clustering of mechanisms

Prioritize the Most Effective Compounds

Rank-ordered Compound Listing

Example from recent Neuro Disease Screen:
- Compound stratification over multiple targets
## Human Disease Models and Capabilities

### Our Therapeutic Assets

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>INDICATION</th>
<th>PRECLINICAL</th>
<th>CLINICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>TARGET ID &amp;</td>
<td>LEAD ID</td>
</tr>
<tr>
<td>VYNT-0126</td>
<td>Rett Syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORAI-xxxx</td>
<td>Rett Syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VYNT-xxxxx</td>
<td>CDK5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Various</td>
<td>Huntington’s Disease</td>
<td>Partner: Origami</td>
<td></td>
</tr>
<tr>
<td>VYNT-xxxxx</td>
<td>Cardiac Fibrosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple programs from early discovery through pre-clinical</td>
<td>Multiple Indications</td>
<td>Vyant Bio</td>
<td></td>
</tr>
</tbody>
</table>

- Each microOrgan Platform can create hundreds of diseases
- Each Disease Model can discover multiple therapeutics
# Human Disease Models and Capabilities

## Our Platform/Disease Model Assets

<table>
<thead>
<tr>
<th>PLATFORMS</th>
<th>DISEASE MODEL</th>
<th>PLATFORM DEVELOPMENT</th>
<th>ASSAY DEVELOPMENT</th>
<th>PHENOTYPIC SCREENING</th>
</tr>
</thead>
<tbody>
<tr>
<td>microBrain®</td>
<td>Multiple Disease Indications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>microHeart®</td>
<td>Multiple Disease Indications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>microPancreas®</td>
<td>Multiple Disease Indications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mid-Brain/Dopaminergic Brain Organoid</td>
<td>Parkinson’s Disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complex Cortical Organoids</td>
<td>Multiple Disease Indications</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Precision Therapeutics

Using genomic and functional biomarkers to stratify and develop the right treatments for the right patients

## Disease Targets

Disease models are created from patient donors, tumor biopsies, genetic engineering, and environmental factors

## Therapeutic Options

Our complex industrialized human systems drive the discovery of small molecules, natural products, and biologics
Achievements

Partnering with 7 of the Top 10 global biopharma companies

1st Neurospheroid\(^1\) Technology
Evaluated within the IQ Consortium
(Data presented to the FDA in March of 2020)

Partnership Case Studies

- Large and small molecule drug discovery
- Custom model development
  - Patient-derived/genetically engineered iPSC lines
- High-throughput screening\(^2\)
- Validated for early neurotoxicity detection
- Lead optimization
- iPSC-based cancer (co-culture) models
  - Brain Cancers & Metastases

\(^1\) Spheroids are industrialized organoids and serve as organ-like models
Seeding & Monetizing Partnerships

Single Partner Lifetime Value

Establish:
Human Organ Platform and Readouts

Co-Create:
Develop Disease Model

Validate:
Manufacture Disease Model

License Out
• Clinical assets / models

Leveraged IP
• Internal Drug Discovery

Revenue

$50k-$500k

$500k - $Millions

Value Capture

Value Creation

Years

Representative Market Deals
(Upfronts + Royalty Potential)

Hemoshear & Takeda
(Upfronts + $470M)

Evotec & Celgene
($65M + $250M)

Insitro & BMS
($50M + $2.1B)

Case Study with top 40 Pharma: Single purchase for tox study and target ID leads to larger custom discovery projects
A Human First Approach

Benefits of Incorporating Human Insights into Traditional Drug Discovery

De-risks

Human relevant *in vitro* screening and *in silico* investigation allows for forecasting of therapeutic success prior to clinic and results in superior tox & efficacy.

Optimizes

Human disease models may lead to synergy between *in vitro* and *in vivo* candidate screening.

Drives Confidence

Clinical candidates rigorously tested with internal regulatory expertise.

Accelerates Timelines

Proprietary technologies potentially maximize patent life, extends commercialization windows, and saves millions in R&D costs.
Investor Contact:
Jennifer K. Zimmons. Ph.D.
Investor Relations
Zimmons International
Communications, Inc.
Email: jzimmons@zimmonsic.com
Phone: +1.917.214.3514